Gut bacteria and treatment outcomes in lymphoma
A prospective evaluation of the gut microbiome as a mediator of lymphoma treatment outcome and systemic immunity
Seeing whether the mix of gut bacteria relates to treatment success and immune responses in people with diffuse large B‑cell lymphoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11261179 on NIH RePORTER |
What this research studies
As a patient, you would provide stool samples before treatment, during therapy, and about a year after, and give weekly blood samples while on treatment. Researchers will sequence stool using 16S and full metagenomic shotgun methods to map bacterial communities and measure immune cell activity in blood. The team will follow roughly 300 patients to see who is in remission at 12 months and link those outcomes to microbiome patterns and immune markers over time. The work aims to find specific gut signatures tied to better or worse treatment responses.
Who could benefit from this research
Good fit: Adults newly diagnosed with untreated diffuse large B‑cell lymphoma who are starting standard therapy and can provide stool and blood samples.
Not a fit: People with other cancer types, those who have already completed lymphoma treatment, or anyone unable to provide required stool or blood samples likely would not benefit from participation.
Why it matters
Potential benefit: If successful, this could help predict who is more likely to respond to lymphoma treatment and point to microbiome-based ways to boost immunity.
How similar studies have performed: Prior studies have linked gut microbiome patterns to treatment response in several solid tumors, but applying this approach to diffuse large B‑cell lymphoma is relatively new.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Diefenbach, Catherine Sibyl — New York University School of Medicine
- Study coordinator: Diefenbach, Catherine Sibyl
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.